Skip to content

In the BioHarmony Drug Report Database

Belantamab mafodotin

Blenrep (belantamab mafodotin) is an antibody pharmaceutical. Belantamab mafodotin was first approved as Blenrep on 2020-08-05. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.
Trade Name Blenrep
Common Name Belantamab mafodotin
Indication multiple myeloma
Drug Class Synthetic analogs of the dolastatin series; monoclonal antibodies: tumors
Belantamab mafodotin
Get full access now